US Orphan Drug Designation Application

Summary by AI BETAClose X

CRISM Therapeutics Corporation has submitted an application to the FDA for Orphan Drug Designation for its Irinotecan-ChemoSeedâ„¢ to treat glioblastoma, a rare brain cancer affecting fewer than 200,000 patients in the US. If granted, the designation would provide benefits including seven years of US market exclusivity, tax credits for clinical research, and waiver of FDA application fees. CRISM has already been awarded an Innovation Passport in the UK and is exploring participation in Project Orbis. The company's Phase 2 clinical trial of Irinotecan-ChemoSeed in surgically resectable glioblastoma is expected to begin in Q1 2026.

Disclaimer*

UK 100

Latest directors dealings